Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.

@article{SezLlorens1998SafetyAP,
  title={Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.},
  author={Xavier S{\'a}ez-Llorens and Elizabeth Casta{\~n}o and Donald Morely Null and James M. Steichen and Pablo J. S{\'a}nchez and Octavio Ramilo and Franklin H. Top and Edward M. Connor},
  journal={The Pediatric infectious disease journal},
  year={1998},
  volume={17 9},
  pages={
          787-91
        }
}
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493 (palivizumab, Synagis) is a humanized monoclonal IgG1 antibody to the fusion protein of RSV, and it is highly active in vitro against RSV A and B strains. OBJECTIVE To describe the safety, tolerance, immunogenicity and pharmacokinetics of monthly intramuscular injections of MEDI-493 among premature infants and children with bronchopulmonary dysplasia and to compare… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…